Avadel Pharmaceuticals to Provide a Corporate Update and Report Fourth Quarter and Full Year 2024 Financial Results on March 3
Rhea-AI Summary
Avadel Pharmaceuticals (Nasdaq: AVDL) announced it will host a conference call and live webcast on March 3, 2025, at 8:30 a.m. ET to discuss its fourth quarter and full year 2024 financial results, along with providing a corporate update. The webcast will be accessible through the company's investor relations website section, and a replay will be available for 90 days afterward. Interested participants are advised to register for the conference call at least 10 minutes before it begins.
Positive
- None.
Negative
- None.
News Market Reaction
On the day this news was published, AVDL declined 1.76%, reflecting a mild negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
DUBLIN, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that it will host a conference call and live webcast at 8:30 a.m. ET on Monday, March 3, 2025, to provide a corporate update and discuss the Company's financial results for the fourth quarter and full year ended December 31, 2024.
A live audio webcast of the call can be accessed by visiting the investor relations section of the Company’s website, www.avadel.com. A replay of the webcast will be archived on Avadel’s website for 90 days following the event. Participants may register for the conference call here and are advised to do so at least 10 minutes prior to joining the call.
About Avadel Pharmaceuticals plc
Avadel Pharmaceuticals plc (Nasdaq: AVDL) is a biopharmaceutical company focused on transforming medicines to transform lives. Our approach includes applying innovative solutions to the development of medications that address the challenges patients face with current treatment options. Avadel’s commercial product, LUMRYZ™, was approved by the U.S. Food & Drug Administration (FDA) as the first and only once-at-bedtime oxybate for the treatment of cataplexy or excessive daytime sleepiness in patients 7 years and older with narcolepsy. For more information, please visit www.avadel.com.
Investor Contact:
Austin Murtagh
Precision AQ
Austin.Murtagh@precisionaq.com
(212) 698-8696
Media Contact:
Lesley Stanley
Real Chemistry
lestanley@realchemistry.com
(609) 273-3162
FAQ
When will Avadel Pharmaceuticals (AVDL) report Q4 and full year 2024 earnings?
How can investors access AVDL's Q4 2024 earnings call?
How long will AVDL's Q4 2024 earnings call replay be available?
What time should participants register for AVDL's Q4 2024 earnings call?
